A carregar...
Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly
In the phase II IM103‐100 study, kidney transplant recipients were first randomized to belatacept more‐intensive‐based (n = 74), belatacept less‐intensive‐based (n = 71), or cyclosporine‐based (n = 73) immunosuppression. At 3‐6 months posttransplant, belatacept‐treated patients were re‐randomized to...
Na minha lista:
| Publicado no: | Am J Transplant |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5724691/ https://ncbi.nlm.nih.gov/pubmed/28758341 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.14452 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|